TrialBMC cancer2021

A Phase 2a cohort expansion study to assess the safety, tolerability, and preliminary efficacy of CXD101 in patients with advanced solid-organ cancer expressing HR23B or lymphoma.

Stephen W Booth et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.